iRhythm Holdings, Inc. (IRTC) Stock Price & How to Invest
Short answer
IRTC is iRhythm Technologies (now iRhythm Holdings), the company behind the Zio patch, the most widely prescribed long-term ambulatory ECG monitor in the US. It is a high-growth (roughly 26% revenue growth), gross-margin-rich medtech that only recently turned adjusted-EBITDA positive, so investors are effectively buying durable category leadership that is still working toward consistent GAAP profitability.
IRTC stock price
As of 2026-07-09, iRhythm Holdings, Inc. (IRTC) last closed at $117.92, down 12.5% over the past year. Over the past 52 weeks it has traded between $101.79 and $189.25.
Prices are daily closing prices from Yahoo Finance and may be delayed. For the live quote, check your broker or iRhythm Holdings, Inc.'s investor relations page. Walnut is informational, not investment advice.
What does iRhythm Holdings, Inc. (IRTC) do?
iRhythm Technologies makes the Zio service, a small adhesive patch that records a patient's heart rhythm continuously for up to 14 days and pairs it with AI-assisted analysis to detect arrhythmias such as atrial fibrillation. The device replaced the older Holter-monitor workflow (short-window, wired recorders) with a longer, more comfortable, water-resistant patch that is mailed back for algorithmic analysis and a physician report. Zio has become the most widely prescribed ambulatory ECG monitor in the US, and iRhythm is extending the franchise with a next-generation mobile cardiac telemetry platform (Zio MCT), international expansion, and adjacencies such as sleep apnea and primary-care risk stratification.
The investment picture is a classic high-growth medtech profile. Revenue is compounding in the mid-20s percent, gross margins sit around 70%, and payer coverage now reaches roughly 93% of US lives, but the company is only recently adjusted-EBITDA positive and still posts GAAP net losses. The stock trades at a premium revenue multiple (roughly $4 billion market cap on under $1 billion of trailing revenue), so the valuation embeds continued volume growth, margin expansion, and successful new-product launches. That combination makes IRTC sensitive to reimbursement rate changes, FDA outcomes, and any slowdown in prescription volumes.
What's driving iRhythm Holdings, Inc. (IRTC)?
1. Zio volume growth and category leadership
The core Zio service continues to take share from legacy Holter monitors, which have fallen from about 80% of the market to roughly 40% as long-term continuous monitoring becomes standard of care. Q1 2026 revenue rose about 26% year over year to roughly $199 million, driven by sustained volume demand across the customer base. As the most widely prescribed ambulatory ECG monitor in the US, iRhythm benefits from installed physician habit and a large recurring stream of new patient prescriptions.
2. Next-generation Zio MCT and AI
iRhythm has submitted its next-generation Zio MCT (mobile cardiac telemetry) platform to the FDA and reaffirmed a first-half 2027 launch target for the AI-enabled version. MCT is a higher-acuity, real-time monitoring category that expands the addressable market beyond the mail-back patch. Deeper AI in the analysis pipeline is also positioned as a driver of both accuracy and margin over time.
3. Margin expansion toward profitability
Gross margin sits near 71% and the company turned adjusted-EBITDA positive, guiding to a full-year 2026 adjusted-EBITDA margin of roughly 12% to 13%. Operating leverage on a largely fixed analysis and sales infrastructure means incremental volume can flow through at high margins. The narrative has shifted from pure top-line growth toward a structural path to sustained profitability.
4. New markets and payer coverage
Growth catalysts include international expansion, deeper penetration in primary care and population health through risk-stratification partnerships, and adjacencies such as obstructive sleep apnea. US payer coverage now reaches about 93% of lives, reducing reimbursement friction for prescribers. These channels give iRhythm several independent levers to extend growth beyond its core cardiology base.
What are the risks to iRhythm Holdings, Inc. (IRTC)?
Regulatory risk is material: iRhythm has been working through FDA warning-letter remediation, which raises compliance costs and can create clearance timing uncertainty for new products like Zio MCT. Reimbursement is the other central risk, since a large share of revenue depends on CMS and commercial payer rates that can be cut or restructured. The company still reports GAAP net losses and trades at a premium revenue multiple, so any volume slowdown, pricing pressure, or launch delay could compress the stock sharply. Competition from larger, better-capitalized players (Philips, Boston Scientific) and the possibility of equity issuance under a shelf registration add further risk. Investors should size positions with the understanding that medtech reimbursement and regulatory outcomes are difficult to predict.
How is iRhythm Holdings, Inc. (IRTC) valued? (approximate, JULY 2026)
A simple financial snapshot. These are approximations and refresh quarterly; for current figures see iRhythm Holdings, Inc.'s investor relations page or your broker.
- Revenue (TTM): ~$790M
- Q1 2026 revenue growth: ~26% YoY
- Gross margin: ~71%
- FY2026 revenue guidance: ~$875M-$885M
- Market cap: ~$4.2B
- Cash and investments: ~$550M
IRTC trades at a premium price-to-sales multiple (roughly $4 billion of market value on under $1 billion of trailing revenue), typical of a high-growth medtech that is still scaling toward consistent GAAP profitability. The company is adjusted-EBITDA positive and guides to a 12% to 13% adjusted-EBITDA margin for 2026, but it still posts GAAP net losses. The valuation therefore leans heavily on continued volume growth and margin expansion rather than current earnings.
Who competes with iRhythm Holdings, Inc. (IRTC)?
Large diversified medtech
Philips (which acquired BioTelemetry) and Boston Scientific (which acquired Preventice Solutions) offer competing ambulatory cardiac monitoring services with far larger balance sheets and broader hospital relationships. GE Healthcare and other cardiology equipment makers also compete across the monitoring landscape.
Legacy monitoring technology
Traditional Holter monitors and short-window event recorders remain the incumbent alternatives that Zio is displacing. Their share has fallen from roughly 80% to around 40% of the market, and that shift toward long-term continuous monitoring is a core part of iRhythm's growth thesis.
Focused monitoring and diagnostics players
Smaller and regional cardiac-monitoring service providers, plus emerging patch and wearable ECG entrants, compete on price, turnaround, and physician relationships in what remains a fragmented market.
How to invest in iRhythm Holdings, Inc. (IRTC)
There are three common ways to get IRTC exposure. Buy shares (or fractional shares) directly at any major broker. Hold an ETF that includes it, which spreads the position across many companies. Or build it into a focused thematic basket, so IRTC sits alongside other stocks that express the same thesis.
Walnut takes the basket route. Describe a thesis where IRTC fits (for example “AI infrastructure” or “dividend-growth large-caps”) and the AI proposes 5 to 6 constituents with target weights. You review the plan and fund it through your own broker when you're ready.
The bottom line on iRhythm Holdings, Inc. (IRTC)
IRTC is a category-leading cardiac-monitoring growth story whose reward depends on continued volume gains and margin scaling against real regulatory and reimbursement risk.
More on iRhythm Holdings, Inc. (IRTC)
Whether IRTC is worth buying today depends more on your time horizon and what you already hold than on any single call. We walk through valuation, what would have to go right, and the risks in is IRTC a buy?, and where the stock could go from here in the IRTC stock forecast.
For income investors, whether IRTC pays a dividend and how the payout looks is covered in does IRTC pay a dividend?
Build a basket around IRTC with Walnut
Use iRhythm Holdings, Inc. as one constituent in a thematic basket Walnut's AI helps you assemble. Describe a thesis you believe in, the AI proposes the holdings and weights, and you approve before any broker order.
FAQ
What does iRhythm Technologies (IRTC) do?
+
iRhythm makes the Zio service, an adhesive patch that continuously records a patient's heart rhythm for up to 14 days. The patch is mailed back and analyzed with AI-assisted algorithms to detect arrhythmias like atrial fibrillation, then a report is sent to the prescribing physician.
Is IRTC profitable?
+
iRhythm is adjusted-EBITDA positive and guides to a roughly 12% to 13% adjusted-EBITDA margin for 2026, but it still reports GAAP net losses. Q1 2026 showed a smaller net loss than the prior year alongside about 26% revenue growth, so profitability is improving but not yet consistent on a GAAP basis.
How fast is iRhythm growing?
+
Revenue grew about 26% year over year in Q1 2026 to roughly $199 million, and the company raised full-year 2026 guidance to about $875 million to $885 million, implying roughly 17% to 18% annual growth. Growth is driven by rising Zio prescription volumes and expanding payer coverage.
What is the Zio MCT and why does it matter?
+
Zio MCT is iRhythm's next-generation mobile cardiac telemetry platform, submitted to the FDA with an AI-enabled version targeted for a first-half 2027 launch. It expands iRhythm into real-time, higher-acuity monitoring, a larger addressable market beyond the mail-back patch.
Who competes with iRhythm?
+
Major competitors include Philips (which acquired BioTelemetry) and Boston Scientific (which acquired Preventice), along with GE Healthcare and numerous smaller monitoring providers. Legacy Holter monitors remain the incumbent technology that Zio is steadily displacing.
What are the biggest risks for IRTC?
+
The main risks are regulatory (FDA warning-letter remediation and clearance timing for new products) and reimbursement (dependence on CMS and commercial payer rates). Its premium valuation, ongoing GAAP losses, and competition from larger firms add to the risk profile.
Why does IRTC trade at such a high valuation?
+
IRTC carries a roughly $4 billion market cap on under $1 billion of trailing revenue, a premium price-to-sales multiple common for high-growth medtech. The valuation reflects expectations of continued volume growth, margin expansion, and successful new-product launches rather than current earnings.
How can someone invest in IRTC?
+
IRTC trades on the Nasdaq and can be bought through any standard brokerage account, as a single stock or as part of a thematic basket of healthcare or medtech names. Because it is a volatile, pre-consistent-profit growth stock, many investors weigh position sizing and diversification carefully. Walnut is not an investment adviser and this is not a recommendation.
Walnut is informational, not investment advice. Financial figures on this page are approximations; always verify current numbers with iRhythm Holdings, Inc.'s investor relations page or your broker before making investment decisions.